Error loading player: No playable sources found

Session II: Mass Spectrometry in Cell & Gene Therapy

Date
September 11, 2024
This product is not available for individual purchase, but it is available as part of the following products:

Session Chairs: : Rich Rogers, Umoja Biopharma and Chris Yu, Genentech, A Member of the Roche Group


Mass spectrometry (MS) has emerged as a powerful analytical tool in the field of cell and gene therapy. As these therapies continue to revolutionize medicine, understanding their complex processes and ensuring consistent product quality become critical objectives. In this session, we explore how MS-based analytical technologies are advancing our understanding and the manufacturing of cell and gene therapy drug products.

Session Speakers:


A Novel In-Vitro Expression LC/MS/MS Assay for mRNA Vaccine Characterization

Olga Friese, Pfizer, Inc.


Characterising Viral Vectors for Gene Therapy using Mass Spectrometry on Different Levels

Jonathan Bones, NIBRT


Enabling Biopharmaceutical Applications of Electrostatic Linear Ion Trap Charge Detection Mass Spectrometry (ELIT-CDMS)

Rebecca D’Esposito, Waters Corporation 


Related Products

Thumbnail for Session VII: MS Trends in Regulatory Research, Review, and Standard
Session VII: MS Trends in Regulatory Research, Review, and Standard
Session Chairs: Sarah Rogstad_, CDER, FDA,_ and Frances Namuswe, _CDER, FDA_
Thumbnail for Diverse Voices: Breakfast Session
Diverse Voices: Breakfast Session
Diversity is not a _color. _It is who is represented in the workplace, research, and society. Examples include gender diversity, age diversity, ethnic diversity, physical ability and neurodiversity…
Thumbnail for Session VI: Next Generation Investigator Awards
Session VI: Next Generation Investigator Awards
Session Chairs: Richard Rogers, _Umoja Biopharma _and Sarah Rogstad_, CDER, FDA_
Thumbnail for Session IX: Multi-Omics in Process Development
Session IX: Multi-Omics in Process Development
Session Chairs: Chris Chumsae, _Bristol-Myers Squibb Company _and Andrew Mahan, _Johnson & Johnson Innovative Medicine _